Welcome to our dedicated page for Structure Therapeutics ADR SEC filings (Ticker: GPCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Structure Therapeutics Inc. (NASDAQ: GPCR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Structure Therapeutics is incorporated in the Cayman Islands and its American Depositary Shares, each representing three ordinary shares, are registered and listed on the Nasdaq Global Market under the symbol GPCR. The company files reports and current updates with the U.S. Securities and Exchange Commission in connection with its operations and capital markets activities.
Investors reviewing GPCR SEC filings will find current reports on Form 8-K that cover topics such as quarterly financial results, corporate updates, and outcomes of the annual general meeting of shareholders. For example, the company has furnished press releases announcing second and third quarter financial results and business updates via Form 8-K, and has reported shareholder voting results on director elections, auditor ratification, and advisory votes on executive compensation and say-on-frequency matters.
Structure Therapeutics also utilizes an automatic shelf registration statement on Form S-3 to conduct public offerings of American Depositary Shares and pre-funded warrants. Related prospectus supplements and offering documents are filed with the SEC and referenced in the company’s press releases. These filings provide details on the terms of upsized underwritten public offerings, gross proceeds, and the involvement of joint book-running managers and co-managers.
Through this filings page, users can monitor how Structure Therapeutics reports its financial condition, shareholder actions, and significant corporate events in its SEC submissions. Stock Titan enhances access to these documents with tools to quickly locate relevant 8-Ks and registration-related materials and to follow the company’s ongoing reporting history as a Nasdaq-listed clinical-stage biopharmaceutical company focused on oral small molecule GPCR-targeted therapies.
Structure Therapeutics Inc. Schedule 13G discloses that Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin jointly report beneficial ownership of 15,401,751 ordinary shares, representing 8.92% of the class based on 172,610,249 shares outstanding. The position is held through 5,133,917 American Depositary Shares, each convertible into three ordinary shares.
The filing states the reporting persons have shared voting and dispositive power over the shares and no sole voting or dispositive power, includes a joint filing statement on amendment responsibilities, and certifies the stake is not held to change or influence control.
Wellington Management disclosed beneficial ownership of 20,627,307 shares of Structure Therapeutics common stock, representing 11.95% of the class. The filing shows no sole voting or dispositive power and reports shared voting power of 19,646,661 and shared dispositive power of 20,627,307, indicating these securities are managed jointly across Wellington entities. The shares are owned of record by clients of Wellington Investment Advisers rather than by Wellington as principal.
The filing also states the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. One named client, Vanguard Health Care Fund, is identified as an exception to the general statement about clients.
FMR LLC, identified as a 10% owner of Structure Therapeutics Inc. (GPCR), filed a Form 4 reporting an open-market sale on 07/30/2025.
- Securities sold: 26,310 American Depositary Shares (ADS), each representing three ordinary shares.
- Sale price: $17.87 per ADS, implying cash proceeds of roughly $470 k.
- Post-sale indirect holdings: 1,515,558 ADS plus 575,934 ordinary shares (45,120 held by F-Prime Capital Partners Life Sciences Advisors Fund VI LP and 530,814 held by F-Prime Capital Partners Life Sciences Fund VI LP).
- The filing notes that Abigail P. Johnson is a director, Chairman and CEO of FMR LLC and that members of the Johnson family collectively control 49% of FMR’s voting power.
No acquisitions were reported; the sole transaction was the ADS disposition coded “S.” FMR and its affiliated funds remain above the 10% beneficial-ownership threshold.